PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Liver Center, GI Division, Massachusetts General Hospital, Boston, Massachusetts, USA.\', \'Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts,USA.\', \'Department of Infectious Diseases, Brigham and Women\'s Hospital, Boston, Massachusetts,USA.\', \'Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts,USA.\', \'Department of Infectious Diseases, Brigham and Women\'s Hospital and Harvard Medical School, Boston, Massachusetts,USA.\', \'Department of Molecular Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts,USA.\', \'Department of Medicine, Brigham and Women\'s Hospital, Boston, Massachusetts,USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1093/infdis/jiab288
?:doi
?:hasPublicationType
?:journal
  • The Journal of infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 34467988
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Type I, II, and III Interferon Signatures Correspond to Coronavirus Disease 2019 Severity.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all